| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.07 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.084 | 0.07 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.08 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.08 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.08 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.08 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.06 | 0.08 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.08 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.059 | 0.08 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.056 | 0.08 |